跳至主要内容
临床试验/NCT07150676
NCT07150676尚未招募不适用

Base de DOnnées Cliniques et Biologiques harmonisées Pour Une REcherche intégrée à la Prise en Charge Des leucémies aiguës Myéloïdes pédiatriques

Assistance Publique - Hôpitaux de Paris0 个研究点目标入组 2,000 人开始时间: 2025年10月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
2,000
主要终点
Overall survival

研究概览

简要总结

The aim of this project is to study the different diagnostic, predictive, and prognostic profiles, as well as their interrelationships (clinical, biological, genetic) in children with Acute Myeloid Leukemia (AML). Despite numerous research projects on separate cohorts, the prognosis for pediatric AML has not improved.

The project therefore consists of pooling research data and existing clinical and biological data from healthcare in a health data warehouse to increase its power.

As these diseases are rare and genetic subgroups even rarer, it is crucial to combine all these data sets into a single database to statistically validate our observations.

The ultimate goal of this project is to reduce the relapse rate and improve the survival rate of pediatric AML by identifying rare, uncharacterized patient subgroups at high risk of relapse, for whom clinical characteristics and outcomes will be compared with omics data, Leukemia Stem Cells signatures, and drug responses to establish accurate and in-depth profiles.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

年龄范围
— 至 25 Years(Child, Adult)
性别
All
接受健康志愿者
否

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Overall survival

时间窗: Up to 27 years

次要结局

  • Event Free Survival(Up to 27 years)
  • Cumulative incidence of relapse(Up to 27 years)
  • Cumulative incidence of second cancer(Up to 27 years)
  • Incidence of long-term sequelae(Up to 27 years)

研究者

申办方类型
Other
责任方
Sponsor

相似试验